Of the negative tests, 1 patient had a false negative T2MR result despite blood cultures growing C. glabrata. There was only 1 invalid test in our sample. Thirty-six patients were initiated or maintained on anti-fungal therapy at the time of the T2MR test, with micafungin being the most commonly prescribed anti-fungal agent. Negative T2MR patients had a median anti-fungal therapy duration of 2 days (IQR, 0–16). Sixteen patients (44%) had their anti-fungal therapy discontinued within 1 day of the negative T2MR result. There were no patients with a negative T2MR result who subsequently developed candidemia within 30 days after T2MR testing.

Conclusion. Our study showcases the benefit seen with T2MR in curtailing unnecessary anti-fungal exposure. Study limitations include a small cohort and evaluation at a single center. There is an opportunity for this technology to be utilized in anti-fungal stewardship.

Disclosures. All authors: No reported disclosures.

271. Fungal Diagnostic Studies in Histoplasmosis
Gayatri Krishnan, MD; Margaret Power, BS; J Ryan. Bariola, MD and Ryan K. Dare, MD, MS; 1University of Arkansas for Medical Sciences, Little Rock, Arkansas; 2University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

Background. Histoplasmosis (histo) is a common cause of invasive fungal infection in endemic regions where accurate diagnosis is difficult without direct tissue culture or pathology. Indirect fungal antigen testing for various fungal pathogens is typically performed to assist with diagnostic workup though cross-reaction can lead to difficulty interpreting results. We aimed to evaluate the prevalence of positive antigen testing for non-Histoplasma fungal pathogens in patients with proven invasive histo.

Methods. We performed a retrospective review of adult patients with proven invasive histo from 2010–2018 at our institution. For inclusion purposes, histo was confirmed by either fungal culture and/or cytology. Patient demographics, clinical characteristics and results of fungal antigen testing for Histoplasma, Blastomyces, Aspergillus, Cryptococcus and β-D-glucan were evaluated. Two different urine Histoplasma antigen assays were used during the study period.

Results. 271 (31%) of 872 patients diagnosed with histo during the study period had culture or cytology evidence of disease and were included in all further analysis. Thirty-two (56%) of these patients were male, 35 (61.4%) were Caucasian and the mean age was 50.1 years. HIV (20; 35%) and being on immunosuppressive medications (21, 40%) disease. Results of fungal antigen testing are documented in the table. Chi-squared analysis was performed.

Conclusion. There is a frequent cross reaction of non-Histoplasma fungal tests in patients with histo. In our review, there was a high rate of cross reaction with Blastomyces antigen, which can be confusing in regions where both pathogens coexist. Elevation of β-D-glucan was high in these patients. Urine Histoplasma antigen sensitivity was higher with MiraVista testing for disseminated disease in our review. While noninvasive fungal tests are helpful in diagnosis of these infrequent infections, clinicians must maintain knowledge of the clinical differences between these fungal pathogens and be aware of the limitations of these tests. A prospective study is needed to better define differences between individual Histoplasma tests.

TABLE

| Histoplasma | Urine Histoplasma Antigen (%) | Urine Blastomyces Antigen (%) | Serum Cryptococcus Antigen (%) | Serum Aspergillus Antigen (%) | Serum β-D-glucan Antigen (%) | Chi square analysis |
|-------------|-----------------------------|-----------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------|
| Acute pneumonia (n=18) | 1/2 (0.5) | 12/18 (67) | 0/1 (0) | 0/1 (0) | 0/1 (0) | N/A |
| Chorionic pneumonia (n=7) | 0/2 (0) | 4/7 (57) | 0/2 (0) | 0/2 (0) | 0/2 (0) | N/A |
| Disseminated (n=40) | 2/17 (12%) 1/21 (5) | 0/18 (22) | 12/19 (63) | 2/24 (10) | 21/24 (90) | N/A |
| Total | 30/64 (47) 9/11 (82) | 22/21 (103) | 26/36 (72) | 12/25 (48) | 13/26 (49) | 21/29 (75) |

* Chi square analysis

Disclosures. All authors: No reported disclosures.

273. Low Positive Predictive Value of β-D-Glucan in Hematology Patients Receiving Antimold Prophylaxis
Eui Jin Chang, MD; Kang Il Jun, MD; Song Mi Moon, MD, PhD; Wan Beom Park, MD, PhD; Ji Hwan Bang, MD, PhD; Eu Suk Kim, MD, PhD; Sang Won Park, MD, PhD; Hong Bin Kim, MD, PhD; Nam-Joong Kim, MD, PhD; Chang Kyoung Kung, MD, PhD; and Myoung Soon Oh, MD, PhD. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Seoul-Tukyolbi, Republic of Korea; 2Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Kyonggi-do, Republic of Korea

Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

Background. Detection of β-d-glucan (BDG) in serum is recognized as the mycological evidence in the diagnosis of invasive fungal infection (IFI). However, its diagnostic value in low prevalence of IFI has not been elucidated. We aimed to examine the performance of BDG in hematology patients receiving antimold prophylaxis.

Methods. We retrospectively reviewed all BDG results performed for the purpose of diagnosis or surveillance for IFI in hematology patients receiving posaconazole or micafungin prophylaxis from January 2017 to February 2019 in a tertiary hospital. At least two consecutive positive results of BDG were regarded as positive BDG. All the episodes were classified into true-positive (TP, positive BDG with probable/proven IFI), true-negative (TN, negative BDG without probable/proven IFI), false-positive (FP, positive BDG without probable/proven IFI), false-negative (FN, negative BDG with probable/proven IFI), and nonevaluable (could not be determined for the occurrence of breakthrough IFI). When BDG test was performed in the setting of persistent fever ≥72 hours in spite of broad-spectrum antibiotics or with a suspicion of IFI, it was defined as diagnostic BDG episode, while others were defined as a surveillance BDG episode.

Results. Of a total of 140 episodes, 24 episodes were non-evaluable. Among 116 evaluable episodes, 75 received induction chemotherapy for acute leukemia or myelodysplastic syndrome, 35 underwent stem cell transplantation, and 10 had intensive treatment for graft-vs.-host disease. There were three episodes of probable/proven IFI (2.6%). Ninety-one (78.4%) were performed with diagnostic purpose, while 25 (21.6%) were performed for surveillance. TP, TN, FP, and FN were 2 (1.7%), 91, 22, and 1, respectively. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were 66.7%, 80.5%, 8.3% and 98.8%, respectively. PPV was 13.3% and 0% in diagnostic and surveillance BDG episodes, respectively.

Conclusion. The PPV of BDG was low in hematology patients receiving antimold prophylaxis, even in the diagnostic-driven episodes. The routine screening of BDG is not helpful, and the BDG test may be used for exclusion of IFI rather than for diagnosis in these patients.

278. Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy vs. Solid Tumor
Rita Vasudevan Dhillon, MBBS, Meulena Khalil, M.D., John F. Resetariz, M.D., Dima Dandachi, M.D.P, Ray Y. Hachem, M.D., Ying Jiang, M.S.; Anne-Marie Hajjar Chaftari, M.D. and Issam I. Raad, M.D. 1Medical College of Georgia Medical Center, Augusta, Georgia; 2The University of Texas MD Anderson Cancer Center, Houston, Texas; 3University of Missouri, Columbia, Missouri; 4MD Anderson Cancer Center, Houston, Texas

Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM

* indocyanine green fluorescence therapy (52.1%); ** MRI and PET-CT correlation (75.2%); *** graft-versus-host disease (17.7%)

Background. Over the years, the profile of patients with invasive pulmonary aspergillosis (IPA) has extended beyond the commonly associated population with hematologic malignancy (HM) and is now comprising patients with solid tumors and patients with lung diseases. We therefore aimed to compare the clinical characteristics, diagnostic approach and therapeutic outcome of IPA in cancer patients with hematologic malignancies vs. solid tumor (ST).

Methods. We conducted a retrospective study evaluating consecutive cases of proven and probable IPA from March 2004 to December 2016 in a tertiary cancer center. We included patients >18 years with an underlying ST, HM, or Hematopoietic Cell Transplantation (HCT) within 1 year of IPA diagnosis.

Results. A total of 311 patients were analyzed: 225 had HM including HCT and 86 ST. Patients with ST were more likely to have had COPD (33% vs. 8%, P < 0.01) or other underlying pulmonary diseases when compared with HM patients (76% vs. 43%, P < 0.01). Radiation therapy prior to the infection was also notably higher in the ST group than the HM group (48% vs. 14%, P < 0.01). Patients with HM were more likely to have received steroid (38% vs. 15%, P = 0.0001) and have concurrent neutropenia 37% vs. 2% (P = 0.0001). A. fumigatus was most commonly recovered in patients with ST than in patients with HM (66% vs. 38%, P < 0.01). Monotherapy and voriconazole based primary anti-fungal therapy were more often prescribed in patients with ST than in patients with HM (87% vs. 56%, P < 0.0001 and 77% vs. 53%, P = 0.0002 respectively). Complete or partial successful response to therapy was recorded in 66% of patients with ST compared with 40% in the HM group (P = 0.0001). IPA attributable mortality within 12 weeks was significantly higher in the HM than in the ST group (30% vs. 18%, P = 0.04).

Conclusion. Monotherapy with voriconazole were more prescribed in patients with ST than in patients with HM. Patients with ST had a better response to antifungal therapy and a lower IPA attributable mortality within 12 weeks compared with those with HM.

Disclosures. All authors: No reported disclosures.
Testing in hospitalized patients appears to offer little benefit. Present with respiratory symptoms, abnormal imaging, and potential fungal exposure. 84% was to cease diagnostic workup (table).

In clinic, but in 0/19 tested as inpatients (P < 0.001). Six patients (10%) had positive serology, but antifungals were started only in abnormal CT findings (nodules 55%, ground glass opacities 18%, and consolidation 74%). Median illness duration was 30 days (range 1–720). Respiratory symptoms pre-existing (27/62: 44%), with Arizona being the most common destination (20/27: 31%) were tested in the hospital and had a median stay of 8 days (range 1–48). Median Charlson score was 4 (range 0–12). Travel to an endemic area for coccidioidomycosis (31%) were tested in the hospital and had a median stay of 8 days (range 1–48).

**Results.** Of 127 patients tested, 62 (49%) had only serologic testing. Patients were predominantly males (95%) with a median age of 66 years (range 27–93). Nineteen (31%) were tested in the hospital and had a median stay of 8 days (range 1–48). Median Charlson score was 4 (range 0–12). Travel to an endemic area for coccidioidomycosis was frequent (27/62: 44%), with Arizona being the most common destination (20/27: 74%). Median illness duration was 30 days (range 1–720). Respiratory symptoms predominated (43/62: 69%), followed by nonspecific (6/62: 10%), neurologic (5/62: 8%), and musculoskeletal (2/62: 3%) symptoms. Five (8%) were asymptomatic. Abnormal imaging was common, with 27/62 (44%) patients having an abnormal chest radiograph (consolidation 15%, nodules 11%, and interstitial pattern 8%), and 44/62 (71%) having abnormal CT findings (nodules 55%, ground glass opacities 18%, and consolidation 15%). Six patients (10%) had positive serology, but antifungals were started only in one case. Fungal serology results impacted management in 19/43 (44%) patients seen in clinic, but in 6/19 tested as inpatients (P < 0.001). The most common action (16/19: 84%) was to cease diagnostic workup (table).

**Conclusion.** Fungal serologies can be useful in patients evaluated in clinic who present with respiratory symptoms, abnormal imaging, and potential fungal exposure. Testing in hospitalized patients appears to offer little benefit.

---

**274. Impact of Fungal Serologies in the Management of Veteran Patients with Suspected Endemic Mycoses**

Eloy E. Ordaya, MD; and Dimitri M. Drekonja, MD, MS; University of Minnesota, Saint Paul, Minnesota; Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota

**Session:** 40. Fungal Diagnostics

**Thursday, October 3, 2019: 12:15 PM**

**Background.** Endemic mycoses are caused by the dimorphic fungi Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides species. Histoplasmosis and blastomycosis are endemic in Minnesota, with travel to coccidioidomycosis endemic areas being common. Diagnosis is challenging, in part due to confusion regarding laboratory testing. In our institution, we have observed that fungal serologies are often ordered when such infections are suspected, but results rarely seem to affect management. We reviewed the impact of serologic testing on the management of a Midwest veteran population.

**Methods.** Retrospective, observational study of patients with any serologic testing for endemic mycoses performed from January 2014 to December 2018 at the Minneapolis VA Health Care System. To focus evaluation on the utility of serologic testing, we excluded patients with fungal antigen testing.

**Results.** Nineteen patients (95%) with a median age of 66 years (range 27–93). Nineteen (31%) were tested in the hospital and had a median stay of 8 days (range 1–48). Median Charlson score was 4 (range 0–12). Travel to an endemic area for coccidioidomycosis (31%) were tested in the hospital and had a median stay of 8 days (range 1–48). Median Charlson score was 4 (range 0–12).

**Conclusion.** Fungal serologies can be useful in patients evaluated in clinic who present with respiratory symptoms, abnormal imaging, and potential fungal exposure. Testing in hospitalized patients appears to offer little benefit.

---

**Disclosures.** All authors: No reported disclosures.

---

**OFID 2019:6 (Suppl 2) • S151**